Summary
Mechanisms of resistance to Tomudex include increased thymidylate synthase activity, as well as reduced intracellular drug uptake and polyglutamation. However, little is known about other mechanisms of resistance, such as a possible protection against Tomudex-induced apoptosis mediated by bcl-2. We transfected the MDA-MB-435 human breast cancer cell line, which is characterized by a mutated p53 gene, with cDNA of the bcl-2 gene and generated two clones (MDA-bcl4 and MDA-bcl7) characterized by bcl-2 expression twofold and fourfold that observed in the control cell clone (MDAneo). A concomitant overexpression of p21wafl was also detected in the MDA-bcl7 clone. The MDA-bcl4 clone was three times more resistant to a 24-h Tomudex exposure than the MDAneo clone, whereas the MDA-bcl7 clone was as sensitive to Tomudex as the control cell clone. A lower sensitivity of the MDA-bcl4 clone than MDAneo and MDA-bcl7 clones to 5-fluorouracil and gemcitabine was also observed. No significant difference was noted in the susceptibility of clones to fludarabine and methothrexate. Basal levels of thymidylate synthase activity were superimposable in the three clones. Tomudex induced a marked accumulation of cells in the S phase in all the clones. However, an apoptotic hypodiploid DNA peak and the characteristic nuclear morphology of apoptosis were observed only in the MDA-bcl7 clone after exposure to Tomudex. No difference in the treatment-induced modulation of proteins involved in cell cycle progression (cyclin A, cdk2, pRB, E2F-1) and apoptosis (bcl-2, bax) was observed in the three clones. The only exception was that the expression of p21wafl in the MDA-bcl4 clone was inducible at a Tomudex concentration much higher than that required to induce the protein in the other clones. Overall, the results indicate that bcl-2 and p21wafl proteins concur in determining the cellular profile of sensitivity/resistance to Tomudex.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Blackledge, G (1998). New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed (‘Tomudex’). Br J Cancer 77: 29–37.
Chellappan, SP, Hiebert, S, Mudryj, M, Horowitz, JM & Nevins, JR (1991). The E2F transcription factor is a cellular target for Rb protein. Cell 65: 1053–1061.
Chen, YQ, Cipriano, SC, Arenkiel, JM & Miller, FR (1995). Tumor suppression by p21wafl. Cancer Res 55: 4536–4539.
Cunningham, D, Zalcberg, JR, Rath, U, Olver, I, Van Cutsem, E, Svensson, C, Seitz, JF, Harper, P, Kerr, D, Perez-Manga, G, Azab, M, Seymour, L, Lowery, K & the ‘Tomudex’ Colorectal Cancer Study, GROUP (1995). ‘Tomudex’ (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31: 1945–1954.
Drake, JC, Allegra, CJ, Moran, RG & Johnston, PG (1996). Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Biochem Pharmacol 51: 1349–1355.
El-Deiry, WS, Harper, JW, O’Connor, PM, Velculescu, VE, Canman, CE, Jackman, J, Pietenpol, JA, Burrel, M, Hill, DE, Wang, Y, Wiman, KG, Mercer, WE, Kastan, MB, Kohn, KW, Elledge, SJ, Knzler, KW & Vogelstein, B (1994). WAFl/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169–1174.
Fisher, TC, Milner, AE, Gregory, CD, Jackman, AL, Aherne, GW, Hartley, JA, Dive, C & Hickman, JA (1993). bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53: 3321–3326.
Freemantle, SJ, Jackman, AL, Kelland, LR, Calvert, AH & Lunec, J (1995). Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694. Br J Cancer 71: 925–930.
Gartenhaus, RB, Wang, P & Hoffmann, P (1996). Induction of the WAFl/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc Natl Acad Sci USA 93: 265–268.
Ikeda, MA, Jakoi, L & Nevins, JR (1996). A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc Natl Acad Sci USA 93: 3215–3220.
Jackman, AL & Calvert, AH (1995). Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6: 871–881.
Jackman, AL, Marshaman, PR, Moran, RG, Kimbell, R, O’Connor, BM, Hughes, LR & Calvert, AH (1991a). Thymidilate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N 10-substituted-5,8-dideazafolates. Adv Enzyme Regulation 31: 13–27.
Jackman, AL, Taylor, GA, Gibson, W, Kimbell, R, Brown, M, Calvert, AH, Judson, IR & Hughes, LR (1991b). ICI1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579–5586.
Jackman, AL, Gibson, W, Brown, M, Kimbell, R & Boyle, FT (1993). The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI1694. In:Proceedings of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation. Advances in Experimental Medicine and Biology, Rustum YM Plenum Press: New York 339: 265–276.
Jackman, AL, Farrugia, DC, Gibson, W, Kimbell, R, Harrap, KR, Stephens, TC, Azab, M & Boyle, FT (1995a). ZD1694 (tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 31: 1277–1282.
Jackman, AL, Kelland, LR, Kimbell, R, Brown, M, Gibson, W, Aherne, GW, Hardcastle, A & Boyle, FT (1995b). Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (tomudex) in one mouse and three human cell lines. Br J Cancer 71: 914–924.
Judson, IR (1997). ‘Tomudex’ (raltitrexed) development: preclinical, phase I and II studies. Anti-Cancer Drugs 8: S5–S9.
Kelland, JR, Kimbell, R, Hardcastle, A, Aherne, GW & Jackman, AL (1995). Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. Eur J Cancer 31: 981–986.
Kinsella, AR, Smith, D & Pickard, M (1997). Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 75: 935–945.
Kroemer, G (1997). The proto-oncogene bcl-2 and its role in regulating apoptosis. Nature Med 3: 614–620.
Li, WW, Fan, J, Hochhauser, D & Bertino, JR (1997). Overexpression of p21wafl leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Cancer Res 57: 2193–2199.
Lu, K, Yin, M-B, McGuire, JJ, Bonmassar, E & Rustum, YM (1995). Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Biochem Pharmacol 50: 391–398.
O’Connor, PM, Jackman, J, Bae, I, Myers, TG, Fan, S, Mutoh, M, Scudiero, DA, Monks, A, Sausville, EA, Weinstein, JN, Friend, S, Fornace, AJ & Kohn, KW (1997). Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlation with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285–4300.
Panadero, A, Yin, M-B, Voigt, W & Rustum, YM (1995). Contrasting patterns of DNA fragmentation induced by thymidylate synthase inhibitors, ZD1694 and AG-331. Oncol Res 7: 73–81.
Pinard, M-F, Jolivet, J, Ratnam, M, Kathmann, I, Molthoff, C, Westerhof, R, Schornagel, JH & Jansen, G (1996). Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate. Cancer Chemother Pharmacol 38: 281–288.
Prabhu, NS, Blagosklonny, MV, Zeng, YX, Hu, GS, Waldman, T & El-Deiry, WS (1996). Suppression of cancer cell growth by adenovirus expressing p21WAFl/CIP1 deficient in PCNA interaction. Clin Cancer Res 2: 1221–1229.
Russo, T, Zambrano, N, Esposito, F, Ammendola, R, Cimino, F, Fiscella, M, Jackman, J, O’Connor, PM, Anderson, CW & Appella, E (1995). A p53-independent pathway for activation of WAFl/CIP1 expression following oxidative stress. J Biol Chem 270: 29386–29391.
Rustum, YM, Harstrick, A, Cao, S, Vanhoefer, U, Yin, M-B, Wilke, H & Seeber, S (1997). Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 15: 389–400.
Sheikh, MS, Li, X-S, Chen, J-C, Shao, Z-M, Ordonez, JV & Fontana, JA (1994). Mechanisms of regulation of WAFl/CIP1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9: 3407–3415.
Sheikh, MS, Rocheort, H & Farcia, M (1995). Overexpression of p21 WAFl/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11: 1899–1905.
Sherr, CJ (1996). Cancer cell cycles. Science 274: 1672–1677.
Silvestrini, R, Zaffaroni, N, Costa, A, Orlandi, L, Villa, R & Hendriks, HR (1993). Flunarizine as a modulator of doxorubicin resistance in human colon-adenocarcinoma cells. Int J Cancer 55: 363–639.
Smith, I, Jones, A, Spielmann, M, Namer, M, Green, MD, Bonneterre, J, Wander, HE, Hatschek, T, Wilking, N, Zalcberg, J, Spiers, J & Seymour, L (1996). A phase II study in advanced breast cancer: ZD1694 (‘Tomudex’) a novel direct and specific thymidylate synthase inhibitor. Br J Cancer 74: 479–481.
Van der Wilt, CL, Pinedo, HM, Smid, K & Peters, GJ (1992). Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 52: 4922–4928.
Van Cutsem, E (1997). Future developments with ‘tomudex’ (raltitrexed). Anti-Cancer Drug 8: S33–S38.
Westerhof, GR, Rijnboutt, S, Schornagel, JH, Pinedo, HM, Peters, GJ & Jansen, G (1995). Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Cancer Res 55: 3795–3802.
Xiong, Y, Hannon, GJ, Zhang, H, Casso, D, Kobayashi, R & Beach, D (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Orlandi, L., Bearzatto, A., Abolafio, G. et al. Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. Br J Cancer 81, 252–260 (1999). https://doi.org/10.1038/sj.bjc.6690685
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690685
Keywords
This article is cited by
-
BCL7A as a novel prognostic biomarker for glioma patients
Journal of Translational Medicine (2021)
-
Utility of Technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer
Breast Cancer (2002)
